Red yeast rice repairs kidney damage and reduces inflammatory transcription factors in rat models of hyperlipidemia

Ding,Mei; Si,Daoyuan; Zhang,Wenqi; Feng,Zhaohui; He,Min; Yang,Ping

doi:10.3892/etm.2014.2035

Red yeast rice repairs kidney damage and reduces inflammatory transcription factors in rat models of hyperlipidemia

Authors:
- Mei Ding
- Daoyuan Si
- Wenqi Zhang
- Zhaohui Feng
- Min He
- Ping Yang
View Affiliations

Affiliations: Department of Cardiology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
Published online on: October 21, 2014 https://doi.org/10.3892/etm.2014.2035
Pages: 1737-1744

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Xuezhikang (XZK), an extract of red yeast rice, has been widely used for the management of hyperlipidemia and coronary heart disease (CHD); however, the effects of XZK treatment on kidney injury have not yet been fully identified. The aim of the current study was to evaluate the effects of XZK on the kidneys and investigate the related mechanisms in a rat model of hyperlipidemia. Thus, the effect on inflammatory transcription factors and kidney damage was investigated with in vitro and in vivo experiments on hyperlipidemic rats following XZK treatment. The results revealed that the plasma levels of total cholesterol (TC), triglycerides (TG) and low‑density lipoprotein‑cholesterol (LDL‑C) were significantly decreased, while the levels of high‑density lipoprotein‑cholesterol (HDL‑C) were significantly upregulated in the XZK treatment group, as compared with those in the hyperlipidemia group (P<0.05). In addition, the results demonstrated that XZK was able to repair the kidney damage caused by hyperlipidemia. Furthermore, the expression levels of the inflammatory transcription factors, tumor necrosis factor‑α and interleukin‑6, were shown to be reduced in the XZK group when compared with the hyperlipidemia group. In summary, XZK reduces kidney injury, downregulates the levels of TG, TC and LDL‑C, as well as the expression levels of inflammatory transcription factors, and upregulates HDL‑C. These results further the understanding of the molecular pathogenic mechanisms underlying hyperlipidemia and aid the development of XZK as an effective therapeutic agent for hyperlipidemia.

View Figures

View References

1	Suk HY, Zhou C, Yang TT, et al: Ablation of calcineurin Aβ reveals hyperlipidemia and signaling cross-talks with phosphodiesterases. J Biol Chem. 288:3477–3488. 2013.
2	Pöss J, Custodis F, Werner C, Weingärtner O, Böhm M and Laufs U: Cardiovascular disease and dyslipidemia: beyond LDL. Curr Pharm Des. 17:861–870. 2011.PubMed/NCBI
3	Vaziri ND and Norris K: Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif. 31:189–196. 2011. View Article : Google Scholar : PubMed/NCBI
4	Burst V and Benzing T: Dyslipidemia treatment and cardiovascular disease in the renal patient. Curr Pharm Des. 17:894–907. 2011. View Article : Google Scholar : PubMed/NCBI
5	Lu ZL, Xu ZM, Kou WR and Zhao SP: Advance in basic and clinical research of Xuezhikang capsule. Chin J Integr Med. 12:85–93. 2006. View Article : Google Scholar : PubMed/NCBI
6	Prospective Studies Collaboration. Lewington S, Whitlock G, Clarke R, et al: Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 370:1829–1839. 2007. View Article : Google Scholar : PubMed/NCBI
7	Shang Q, Liu Z, Chen K, Xu H and Liu J: A systematic review of Xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia. Evid Based Complement Alternat Med. 2012:6365472012.PubMed/NCBI
8	Ma J, Li Y, Ye Q, et al: Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem. 48:5220–5225. 2000. View Article : Google Scholar : PubMed/NCBI
9	Zhu XY, Li P, Yang YB and Liu ML: Xuezhikang, extract of red yeast rice, improved abnormal hemorheology, suppressed caveolin-1 and increased eNOS expression in atherosclerotic rats. PLoS One. 8:e627312013. View Article : Google Scholar : PubMed/NCBI
10	Journoud M and Jones PJ: Red yeast rice: a new hypolipidemic drug. Life Sci. 74:2675–2683. 2004. View Article : Google Scholar : PubMed/NCBI
11	Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T and Fønnebø V: Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med. 1:42006. View Article : Google Scholar
12	Lu Z, Kou W, Du B, et al; Chinese Coronary Secondary Prevention Study Group. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 101:1689–1693. 2008. View Article : Google Scholar : PubMed/NCBI
13	Hong XZ, Li LD and Wu LM: Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol. 34:27–35. 2007. View Article : Google Scholar : PubMed/NCBI
14	Aebi H: Catalase in vitro. Methods Enzymol. 105:121–126. 1984. View Article : Google Scholar
15	Paglia DE and Valentine WN: Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 70:158–169. 1967.PubMed/NCBI
16	Pan D, Zhang D, Wu J, et al: A novel proteoglycan from Ganoderma lucidum fruiting bodies protects kidney function and ameliorates diabetic nephropathy via its antioxidant activity in C57BL/6 db/db mice. Food Chem Toxicol. 63:111–118. 2014.
17	Tietge UJ: Hyperlipidemia and cardiovascular disease: inflammation, dyslipidemia, and atherosclerosis. Curr Opin Lipidol. 25:94–95. 2014. View Article : Google Scholar : PubMed/NCBI
18	Martin SS, Blaha MJ, Blankstein R, et al: Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation. 129:77–86. 2014. View Article : Google Scholar
19	Schaeffner ES, Kurth T, Curhan GC, et al: Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 14:2084–2091. 2003.PubMed/NCBI
20	Mänttäri M, Tiula E, Alikoski T and Manninen V: Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 26:670–675. 1995.PubMed/NCBI
21	Takemura T, Yoshioka K, Aya N, et al: Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int. 43:918–927. 1993. View Article : Google Scholar : PubMed/NCBI
22	Abrass CK: Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol. 24:46–53. 2004. View Article : Google Scholar : PubMed/NCBI
23	Tonelli M, Moyé L, Sacks FM, et al; Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 14:1605–1613. 2003. View Article : Google Scholar : PubMed/NCBI
24	Peev V, Nayer A and Contreras G: Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease. Curr Opin Lipidol. 25:54–60. 2014. View Article : Google Scholar : PubMed/NCBI
25	Shi Y, Guo R, Wang X, et al: The regulation of alfalfa saponin extract on key genes involved in hepatic cholesterol metabolism in hyperlipidemic rats. PLoS One. 9:e882822014. View Article : Google Scholar : PubMed/NCBI
26	Arafa HM: Curcumin attenuates diet-induced hypercholesterolemia in rats. Med Sci Monit. 11:BR228–BR234. 2005.PubMed/NCBI
27	Martin SS, Blaha MJ, Blankstein R, et al: Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation. 129:77–86. 2014. View Article : Google Scholar
28	Tolman KG: The liver and lovastatin. Am J Cardiol. 89:1374–1380. 2002. View Article : Google Scholar : PubMed/NCBI
29	Campese VM: Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs. Clin Exp Nephrol. 18:291–295. 2014. View Article : Google Scholar : PubMed/NCBI
30	Shang Q, Liu Z, Chen K, Xu H and Liu J: A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia. Evid Based Complement Alternat Med. 2012:6365472012.PubMed/NCBI
31	Lin YC, Chiang CH, Chang LT, et al: Simvastatin attenuates the additive effects of TNF-α and IL-18 on the connexin 43 up-regulation and over-proliferation of cultured aortic smooth muscle cells. Cytokine. 62:341–351. 2013.PubMed/NCBI
32	Li Z, Yang S, Lin H, et al: Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 37:343–350. 2003. View Article : Google Scholar : PubMed/NCBI
33	Libby P, Sukhova G, Lee RT and Galis ZS: Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol. 25(Suppl 2): S9–S12. 1995. View Article : Google Scholar : PubMed/NCBI
34	Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:801–809. 1993. View Article : Google Scholar : PubMed/NCBI
35	Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL and Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA. 89:4845–4849. 1992.
36	Fan XF, Deng YQ, Ye L, et al: Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia. Chin J Integr Med. 16:119–123. 2010. View Article : Google Scholar : PubMed/NCBI